<DOC>
	<DOCNO>NCT02019264</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-group study overweight obese subject CV disease and/or multiple CV risk factor .</brief_summary>
	<brief_title>A Study Evaluate Effect Long-term Treatment With BELVIQ ( Lorcaserin HCl ) Incidence Major Adverse Cardiovascular Events Conversion Type 2 Diabetes Mellitus Obese Overweight Subjects With Cardiovascular Disease Multiple Cardiovascular Risk Factors</brief_title>
	<detailed_description>Approximately 12,000 subject randomize two treatment group ratio 1:1 , stratify presence establish CV disease ( approximately 80 % ) CV risk factor without establish CV disease ( approximately 20 % ) . Subjects receive lorcaserin HCl 10 mg BID placebo BID . The study consist 2 phase : Prerandomization Randomization . The Prerandomization Phase last 30 day consist one visit subject screen eligibility . The Randomization Phase consist two period : Treatment Follow-up . The Treatment Period last approximately 5 year approximately 18 visit Follow-up period 30 ( + - 10 day ) end treatment visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Inclusion Criteria 1 . BMI great equal 27 kg/m^2 2 . Subjects able willing comply reducedcalorie diet increase physical activity program 3 . Age great equal 40 year establish CV disease define one following : 1 . History document MI ischemic stroke 2 . History peripheral artery disease 3 . History revascularization ( coronary , carotid , peripheral artery ) 4 . Significant unrevascularized coronary arterial stenosis OR Age great equal 55 year woman great equal 50 year men T2DM without establish CV disease plus least one follow CV risk factor : 1 . Hypertension , currently receive therapy document hypertension 2 . Dyslipidemia , currently take prescription lipidlowering therapy document dyslipidemia 3 . Calculated creatinine clearance great equal 30 less equal 60 mL/min per Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation 4 . High hsCRP 5 . Urinary albumintocreatinine ratio ( ACR ) great equal 30 ug/mg Subjects T2DM may preexist new diagnosis T2DM . A new diagnosis T2DM ( ie , discover Screening ) base 2013 American Diabetes Association ( ADA ) guideline . All T2DM subject must HbA [ 1c ] less 10 % Screening . If subject treat , upon diagnosis need treat antidiabetic agent , T2DM treatment regimen must stable least 3 month prior randomization . Exclusion Criteria 1 . Moderate great symptom congestive cardiac failure ( New York Heart Association [ NYHA ] class III IV ) 2 . Known leave ventricular ( LV ) ejection fraction le 20 % 3 . Moderate great symptom pulmonary hypertension ( PH ) 4 . Known severe valvular disease Moderate renal impairment , severe renal impairment , end stage renal disease ( ESRD ) ( calculate creatinine clearance le 30 mL/min per CKDEPI equation base ideal body weight ) 5 . Severe hepatic impairment 6 . Use product intend weight loss include prescription drug , overthecounter ( OTC ) drug , herbal preparation 7 . Use one serotonergic drug 8 . Use drug know increase risk cardiac valvulopathy prior Screening include , limited : cyproheptadine , amoxapine , TCAs , mirtazapine , pergolide , ergotamine , methysergide , cabergoline 9 . History evidence clinically significant disease ( e.g. , malignancy , cardiac , respiratory , gastrointestinal , renal psychiatric disease ) 10 . Use lorcaserin HCl prior Screening hypersensitivity lorcaserin HCl excipients 11 . Planned bariatric surgery 12 . Females must breastfeed pregnant</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Cardiovascular Disease</keyword>
	<keyword>Multiple Cardiovascular Risk Factors</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>MACE</keyword>
	<keyword>Conversion Diabetes</keyword>
</DOC>